The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker
- 1 January 2001
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 37, 3-10
- https://doi.org/10.1016/s0959-8049(00)00402-0
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviorsBreast Cancer Research and Treatment, 1999
- Prognosis and prediction of response in breast cancer: the current role of the main biological markersCell Proliferation, 1998
- Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiationOncogene, 1997
- The Nottingham prognostic index in primary breast cancerBreast Cancer Research and Treatment, 1992
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992
- REPORTSJNCI Journal of the National Cancer Institute, 1991
- p53 in the Diagnosis of Human NeoplasiaJNCI Journal of the National Cancer Institute, 1991
- Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.Proceedings of the National Academy of Sciences, 1986
- Comparative Study of Harvey-RAS Oncogene Expression with Conventional Clinicopathologic Parameters of Breast CancerOncology, 1986
- Progesterone Receptors as a Prognostic Factor in Stage II Breast CancerNew England Journal of Medicine, 1983